78 results on '"Scheule, Ronald K."'
Search Results
2. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease
- Author
-
Ashe, Karen M., Budman, Eva, Bangari, Dinesh S., Siegel, Craig S., Nietupski, Jennifer B., Wang, Bing, Desnick, Robert J., Scheule, Ronald K., Leonard, John P., Cheng, Seng H., and Marshall, John
- Published
- 2015
- Full Text
- View/download PDF
3. Secreted Gaussia luciferase as a sensitive reporter gene for in vivo and ex vivo studies of airway gene transfer
- Author
-
Griesenbach, Uta, Vicente, Catarina C., Roberts, Megan J., Meng, Cuixiang, Soussi, Samia, Xenariou, Stefania, Tennant, Peter, Baker, Alison, Baker, Eilidh, Gordon, Catherine, Vrettou, Christina, McCormick, Dominique, Coles, Rebecca, Green, Anne-Marie, Lawton, Anna E., Sumner-Jones, Stephanie G., Cheng, Seng H., Scheule, Ronald K., Hyde, Stephen C., Gill, Deborah R., Collie, David D., McLachlan, Gerry, and Alton, Eric W.F.W.
- Published
- 2011
- Full Text
- View/download PDF
4. Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion
- Author
-
Ziegler, Robin J., Salegio, Ernesto A., Dodge, James C., Bringas, John, Treleaven, Christopher M., Bercury, Scott D., Tamsett, Thomas J., Shihabuddin, Lamya, Hadaczek, Piotr, Fiandaca, Massimo, Bankiewicz, Krystof, and Scheule, Ronald K.
- Published
- 2011
- Full Text
- View/download PDF
5. The use of carboxymethylcellulose gel to increase non-viral gene transfer in mouse airways
- Author
-
Griesenbach, Uta, Meng, Cuixiang, Farley, Raymond, Wasowicz, Marguerite Y., Munkonge, Felix M., Chan, Mario, Stoneham, Charlotte, Sumner-Jones, Stephanie G., Pringle, Ian A., Gill, Deborah R., Hyde, Stephen C., Stevenson, Barbara, Holder, Emma, Ban, Hiroshi, Hasegawa, Mamoru, Cheng, Seng H., Scheule, Ronald K., Sinn, Patrick L., McCray, Paul B., Jr., and Alton, Eric W.F.W.
- Published
- 2010
- Full Text
- View/download PDF
6. The role of doxorubicin in non-viral gene transfer in the lung
- Author
-
Griesenbach, Uta, Meng, Cuixiang, Farley, Raymond, Gardner, Aaron, Brake, Maresa A., Frankel, Gad M., Gruenert, Dieter C., Cheng, Seng H., Scheule, Ronald K., and Alton, Eric W.F.W.
- Published
- 2009
- Full Text
- View/download PDF
7. Rapid identification of novel functional promoters for gene therapy
- Author
-
Pringle, Ian A., Gill, Deborah R., Connolly, Mary M., Lawton, Anna E., Hewitt, Anne-Marie, Nunez-Alonso, Graciela, Cheng, Seng H., Scheule, Ronald K., Davies, Lee A., and Hyde, Stephen C.
- Published
- 2012
- Full Text
- View/download PDF
8. In vivo imaging of gene transfer to the respiratory tract
- Author
-
Griesenbach, Uta, Meng, Cuixiang, Farley, Raymond, Cheng, Seng H., Scheule, Ronald K., Davies, Mark H., Wolstenholme-Hogg, Paul C., ten Hove, Willem, van der Hoeven, Paul, Sinn, Patrick L., McCray, Paul B., Jr., Inoue, Makoto, Geddes, Duncan M., Hasegawa, Mamoru, Frankel, Gad, Wiles, Siouxsie, and Alton, Eric W.F.W.
- Published
- 2008
- Full Text
- View/download PDF
9. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy
- Author
-
Marshall, John, McEachern, Kerry Anne, Chuang, Wei-Lien, Hutto, Elizabeth, Siegel, Craig S., Shayman, James A., Grabowski, Greg A., Scheule, Ronald K., Copeland, Diane P., and Cheng, Seng H.
- Published
- 2010
- Full Text
- View/download PDF
10. Endostatin gene transfection using a cationic lipid: advantages of transfection before tumor cell inoculation and repeated transfection
- Author
-
Yano, Motoki, Nakashima, Yoshiaki, Kobayashi, Yoshihiro, Mizuno, Kotaro, Konishi, Akimitsu, Sasaki, Hidefumi, Fukai, Ichiro, Scheule, Ronald K, and Fujii, Yoshitaka
- Published
- 2004
- Full Text
- View/download PDF
11. Assessment of the nuclear pore dilating agent trans-cyclohexane-1,2-diol in differentiated airway epithelium
- Author
-
Griesenbach, Uta, Wilson, Katherine M., Farley, Raymond, Meng, Cuixiang, Munkonge, Felix M., Cheng, Seng H., Scheule, Ronald K., and Alton, Eric W. F. W.
- Published
- 2012
- Full Text
- View/download PDF
12. Limitations of the Murine Nose in the Development of Nonviral Airway Gene Transfer
- Author
-
Griesenbach, Uta, Sumner-Jones, Stephanie G., Holder, Emma, Munkonge, Felix M., Wodehouse, Theresa, Smith, Stephen N., Wasowicz, Marguerite Y., Pringle, Ian, Casamayor, Isabel, Chan, Mario, Coles, Rebecca, Cornish, Nikki, Dewar, Ann, Doherty, Ann, Farley, Raymond, Green, Anne-Marie, Jones, Bryony L., Larsen, Mia D. B., Lawton, Anna E., Manvell, Michelle, Painter, Hazel, Singh, Charanjit, Somerton, Lucinda, Stevenson, Barbara, Varathalingam, Anusha, Siegel, Craig, Scheule, Ronald K., Cheng, Seng H., Davies, Jane C., Porteous, David J., Gill, Deborah R., Boyd, Christopher A., Hyde, Steve C., and Alton, Eric W. F. W.
- Published
- 2010
- Full Text
- View/download PDF
13. Surfactant Protein-D Inhibits Lung Inflammation Caused by Ventilation in Premature Newborn Lambs
- Author
-
Sato, Atsuyasu, Whitsett, Jeffrey A., Scheule, Ronald K., and Ikegami, Machiko
- Published
- 2010
- Full Text
- View/download PDF
14. Surfactant Protein-D and Surfactant Inhibit Endotoxin-Induced Pulmonary Inflammation*
- Author
-
Ikegami, Machiko, Scoville, Elizabeth A., Grant, Shawn, Korfhagen, Thomas, Brondyk, William, Scheule, Ronald K., and Whitsett, Jeffrey A.
- Published
- 2007
- Full Text
- View/download PDF
15. Intratracheal Recombinant Surfactant Protein D Prevents Endotoxin Shock in the Newborn Preterm Lamb
- Author
-
Ikegami, Machiko, Carter, Karen, Bishop, Kimberly, Yadav, Annuradha, Masterjohn, Elizabeth, Brondyk, William, Scheule, Ronald K., and Whitsett, Jeffrey A.
- Published
- 2006
- Full Text
- View/download PDF
16. Role of viral hemagglutinin glycosylation in anti-influenza activities of recombinant surfactant protein D
- Author
-
Boucher Susan, Pan Clark, Tecle Tesfaldet, White Mitchell R, Webby Richard, Hartshorn Kevan L, Moreland Rodney J, Crouch Erika C, and Scheule Ronald K
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Surfactant protein D (SP-D) plays an important role in innate defense against influenza A viruses (IAVs) and other pathogens. Methods We tested antiviral activities of recombinant human SP-D against a panel of IAV strains that vary in glycosylation sites on their hemagglutinin (HA). For these experiments a recombinant version of human SP-D of the Met11, Ala160 genotype was used after it was characterized biochemically and structurally. Results Oligosaccharides at amino acid 165 on the HA in the H3N2 subtype and 104 in the H1N1 subtype are absent in collectin-resistant strains developed in vitro and are important for mediating antiviral activity of SP-D; however, other glycans on the HA of these viral subtypes also are involved in inhibition by SP-D. H3N2 strains obtained shortly after introduction into the human population were largely resistant to SP-D, despite having the glycan at 165. H3N2 strains have become steadily more sensitive to SP-D over time in the human population, in association with addition of other glycans to the head region of the HA. In contrast, H1N1 strains were most sensitive in the 1970s–1980s and more recent strains have become less sensitive, despite retaining the glycan at 104. Two H5N1 strains were also resistant to inhibition by SP-D. By comparing sites of glycan attachment on sensitive vs. resistant strains, specific glycan sites on the head domain of the HA are implicated as important for inhibition by SP-D. Molecular modeling of the glycan attachment sites on HA and the carbohydrate recognition domain of SPD are consistent with these observations. Conclusion Inhibition by SP-D correlates with presence of several glycan attachment sites on the HA. Pandemic and avian strains appear to lack susceptibility to SP-D and this could be a contributory factor to their virulence.
- Published
- 2008
- Full Text
- View/download PDF
17. Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo
- Author
-
Hu Jim, Chow Yu-Hua, Hyde Stephen C, Gill Deborah R, Smith Rbecca L, Painter Hazel, Somerton Luci, Singh Charanjit, Farley Raymond, Garcia Sara, Kitson Chris, Griesenbach Uta, Gray Mike, Edbrooke Mark, Ogilvie Varrie, MacGregor Gordon, Scheule Ronald K, Cheng Seng H, Caplen Natasha J, and Alton Eric WFW
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background The cationic lipid Genzyme lipid (GL) 67 is the current "gold-standard" for in vivo lung gene transfer. Here, we assessed, if GL67 mediated uptake of siRNAs and asODNs into airway epithelium in vivo. Methods Anti-lacZ and ENaC (epithelial sodium channel) siRNA and asODN were complexed to GL67 and administered to the mouse airway epithelium in vivo Transfection efficiency and efficacy were assessed using real-time RT-PCR as well as through protein expression and functional studies. In parallel in vitro experiments were carried out to select the most efficient oligonucleotides. Results In vitro, GL67 efficiently complexed asODNs and siRNAs, and both were stable in exhaled breath condensate. Importantly, during in vitro selection of functional siRNA and asODN we noted that asODNs accumulated rapidly in the nuclei of transfected cells, whereas siRNAs remained in the cytoplasm, a pattern consistent with their presumed site of action. Following in vivo lung transfection siRNAs were only visible in alveolar macrophages, whereas asODN also transfected alveolar epithelial cells, but no significant uptake into conducting airway epithelial cells was seen. SiRNAs and asODNs targeted to β-galactosidase reduced βgal mRNA levels in the airway epithelium of K18-lacZ mice by 30% and 60%, respectively. However, this was insufficient to reduce protein expression. In an attempt to increase transfection efficiency of the airway epithelium, we increased contact time of siRNA and asODN using the in vivo mouse nose model. Although highly variable and inefficient, transfection of airway epithelium with asODN, but not siRNA, was now seen. As asODNs more effectively transfected nasal airway epithelial cells, we assessed the effect of asODN against ENaC, a potential therapeutic target in cystic fibrosis; no decrease in ENaC mRNA levels or function was detected. Conclusion This study suggests that although siRNAs and asODNs can be developed to inhibit gene expression in culture systems and certain organs in vivo, barriers to nucleic acid transfer in airway epithelial cells seen with large DNA molecules may also affect the efficiency of in vivo uptake of small nucleic acid molecules.
- Published
- 2006
- Full Text
- View/download PDF
18. The role of CpG motifs in immunostimulation and gene therapy
- Author
-
Scheule, Ronald K
- Published
- 2000
- Full Text
- View/download PDF
19. Transfection of pulmonary artery segments in lung isografts during storage
- Author
-
Yano, Motoki, Hiratsuka, Masafumi, Mora, Bassem N, Scheule, Ronald K, and Patterson, G.Alexander
- Published
- 1999
- Full Text
- View/download PDF
20. Ex vivo transfection of pulmonary artery segments in lung isografts
- Author
-
Yano, Motoki, Hiratsuka, Masafumi, Nagahiro, Itaru, Mora, Bassem N, Scheule, Ronald K, and Patterson, G.Alexander
- Published
- 1999
- Full Text
- View/download PDF
21. Dysregulation of Multiple Facets of Glycogen Metabolism in a Murine Model of Pompe Disease.
- Author
-
Taylor, Kristin M., Meyers, Elizabeth, Phipps, Michael, Kishnani, Priya S., Cheng, Seng H., Scheule, Ronald K., and Moreland, Rodney J.
- Subjects
GLYCOGEN storage disease type II ,ETIOLOGY of diseases ,GLUCOSIDASES ,CHILD mortality ,ENZYME metabolism ,BIOSYNTHESIS ,CARBOHYDRATE metabolism ,LABORATORY mice - Abstract
Pompe disease, also known as glycogen storage disease (GSD) type II, is caused by deficiency of lysosomal acid α-glucosidase (GAA). The resulting glycogen accumulation causes a spectrum of disease severity ranging from a rapidly progressive course that is typically fatal by 1 to 2 years of age to a slower progressive course that causes significant morbidity and early mortality in children and adults. The aim of this study is to better understand the biochemical consequences of glycogen accumulation in the Pompe mouse. We evaluated glycogen metabolism in heart, triceps, quadriceps, and liver from wild type and several strains of GAA
−/− mice. Unexpectedly, we observed that lysosomal glycogen storage correlated with a robust increase in factors that normally promote glycogen biosynthesis. The GAA−/− mouse strains were found to have elevated glycogen synthase (GS), glycogenin, hexokinase, and glucose-6-phosphate (G-6-P, the allosteric activator of GS). Treating GAA−/− mice with recombinant human GAA (rhGAA) led to a dramatic reduction in the levels of glycogen, GS, glycogenin, and G-6-P. Lysosomal glycogen storage also correlated with a dysregulation of phosphorylase, which normally breaks down cytoplasmic glycogen. Analysis of phosphorylase activity confirmed a previous report that, although phosphorylase protein levels are identical in muscle lysates from wild type and GAA−/− mice, phosphorylase activity is suppressed in the GAA−/− mice in the absence of AMP. This reduction in phosphorylase activity likely exacerbates lysosomal glycogen accumulation. If the dysregulation in glycogen metabolism observed in the mouse model of Pompe disease also occurs in Pompe patients, it may contribute to the observed broad spectrum of disease severity. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
22. Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease.
- Author
-
Cabrera-Salazar, Mario A., DeRiso, Matthew, Bercury, Scott D., Lingyun Li, Lydon, John T., Weber, William, Pande, Nilesh, Cromwell, Mandy A., Copeland, Diane, Leonard, John, Cheng, Seng H., Scheule, Ronald K., and Silman, Israel
- Subjects
ENZYMES ,ENZYME deficiency ,GLYCOSYLCERAMIDASE ,BRAIN ,LABORATORY mice ,NEUROLOGICAL disorders - Abstract
Neuropathic Gaucher disease (nGD), also known as type 2 or type 3 Gaucher disease, is caused by a deficiency of the enzyme glucocerebrosidase (GC). This deficiency impairs the degradation of glucosylceramide (GluCer) and glucosylsphingosine (GluSph), leading to their accumulation in the brains of patients and mouse models of the disease. These accumulated substrates have been thought to cause the severe neuropathology and early death observed in patients with nGD and mouse models. Substrate accumulation is evident at birth in both nGD mouse models and humans affected with the most severe type ofthe disease. Current treatment of non-nGD relies on the intravenous delivery of recombinant human glucocerebrosidase to replace the missing enzyme or the administration of glucosylceramide synthase inhibitors to attenuate GluCer production. However, the currently approved drugs that use these mechanisms do not cross the blood brain barrier, and thus are not expected to provide a benefit for the neurological complications in nGD patients. Here we report the successful reduction of substrate accumulation and CNS pathology together with a significant increase in lifespan after systemic administration of a novel glucosylceramide synthase inhibitor to a mouse model of nGD. To our knowledge this is the first compound shown to cross the blood brain barrier and reduce substrates in this animal model while significantly enhancing its lifespan. These results reinforce the concept that systemically administered glucosylceramide synthase inhibitors could hold enhanced therapeutic promise for patients afflicted with neuropathic lysosomal storage diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
23. Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease.
- Author
-
Ashe, Karen M., Bangari, Dinesh, Li, Lingyun, Cabrera-Salazar, Mario A., Bercury, Scott D., Nietupski, Jennifer B., Cooper, Christopher G. F., Aerts, Johannes M. F. G., Lee, Edward R., Copeland, Diane P., Cheng, Seng H., Scheule, Ronald K., and Marshall, John
- Subjects
BRAIN physiology ,IMINOSUGARS ,GLUCOSYLCERAMIDES ,GLYCOSPHINGOLIPIDS ,LABORATORY mice ,BLOOD-brain barrier ,RESPONSE inhibition ,TAY-Sachs disease ,CENTRAL nervous system ,ENZYME inhibitors ,SANDHOFF disease - Abstract
The neuropathic glycosphingolipidoses are a subgroup of lysosomal storage disorders for which there are no effective therapies. A potential approach is substrate reduction therapy using inhibitors of glucosylceramide synthase (GCS) to decrease the synthesis of glucosylceramide and related glycosphingolipids that accumulate in the lysosomes. Genz-529468, a blood-brain barrier-permeant iminosugar-based GCS inhibitor, was used to evaluate this concept in a mouse model of Sandhoff disease, which accumulates the glycosphingolipid GM2 in the visceral organs and CNS. As expected, oral administration of the drug inhibited hepatic GM2 accumulation. Paradoxically, in the brain, treatment resulted in a slight increase in GM2 levels and a 20-fold increase in glucosylceramide levels. The increase in brain glucosylceramide levels might be due to concurrent inhibition of the non-lysosomal glucosylceramidase, Gba2. Similar results were observed with NB-DNJ, another iminosugar-based GCS inhibitor. Despite these unanticipated increases in glycosphingolipids in the CNS, treatment nevertheless delayed the loss of motor function and coordination and extended the lifespan of the Sandhoff mice. These results suggest that the CNS benefits observed in the Sandhoff mice might not necessarily be due to substrate reduction therapy but rather to off-target effects. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
24. Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease.
- Author
-
Marshall, John, Ashe, Karen M., Bangari, Dinesh, McEachern, KerryAnne, Wei-Lien Chuang, Pacheco, Joshua, Copeland, Diane P., Desnick, Robert J., Shayman, James A., Scheule, Ronald K., and Cheng, Seng H.
- Subjects
GLYCOSPHINGOLIPIDS ,SPHINGOLIPIDS ,LABORATORY mice ,ORGANELLES ,KIDNEY diseases ,GAUCHER'S disease - Abstract
Fabry disease is an X-linked glycosphingolipid storage disorder caused by a deficiency in the activity of the lysosomal hydrolase α-galactosidase A (α-gal). This deficiency results in accumulation of the glycosphingolipid globotriaosylceramide (GL-3) in lysosomes. Endothelial cell storage of GL-3 frequently leads to kidney dysfunction, cardiac and cerebrovascular disease. The current treatment for Fabry disease is through infusions of recombinant α-gal (enzyme-replacement therapy; ERT). Although ERT can markedly reduce the lysosomal burden of GL-3 in endothelial cells, variability is seen in the clearance from several other cell types. This suggests that alternative and adjuvant therapies may be desirable. Use of glucosylceramide synthase inhibitors to abate the biosynthesis of glycosphingolipids (substrate reduction therapy, SRT) has been shown to be effective at reducing substrate levels in the related glycosphingolipidosis, Gaucher disease. Here, we show that such an inhibitor (eliglustat tartrate, Genz-112638) was effective at lowering GL-3 accumulation in a mouse model of Fabry disease. Relative efficacy of SRT and ERT at reducing GL-3 levels in Fabry mouse tissues differed with SRT being more effective in the kidney, and ERT more efficacious in the heart and liver. Combination therapy with ERT and SRT provided the most complete clearance of GL-3 from all the tissues. Furthermore, treatment normalized urine volume and uromodulin levels and significantly delayed the loss of a nociceptive response. The differential efficacies of SRT and ERT in the different tissues indicate that the combination approach is both additive and complementary suggesting the possibility of an improved therapeutic paradigm in the management of Fabry disease. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
25. Detection of CFTR transgene mRNA expression in respiratory epithelium isolated from the murine nasal cavity.
- Author
-
Holder, Emma, Stevenson, Barbara, Farley, Raymond, Hilliard, Tom, Wodehouse, Theresa, Somerton, Lucinda, Larsen, Mia, O'Donoghue, Jean, Coles, Rebecca L., Scheule, Ronald K., Cheng, Seng H., Gill, Deborah R., Hyde, Stephen C., Griesenbach, Uta, Alton, Eric W. F. W., Porteous, David J., and Boyd, A. Christopher
- Abstract
Background When assessing the efficacy of gene transfer agents (GTAs) for cystic fibrosis (CF) gene therapy, we routinely evaluate gene transfer in the mouse nose and measure transfection efficiency by assessing transgene-specific mRNA using the real-time (TaqMan) quantitative reverse transcriptase-polymerase chain reaction. TaqMan is traditionally used to quantify expression in whole tissue homogenates, which in the nose would contain many cells types, including respiratory and olfactory epithelium. Only the respiratory epithelium is a satisfactory model for human airway epithelium and therefore CFTR gene transfer should be specifically assessed in respiratory epithelial cells (RECs). Methods We have compared laser microdissection, pronase digestion and nasal brushing for: (i) the ability to enrich RECs from the wild-type mouse nose and (ii) the length of time to perform the procedure. Using TaqMan, we subsequently assessed gene transfer in enriched RECs after nasal perfusion of GL67A/pCF1-CFTR complexes in a CF mouse model. Results Laser microdissection successfully isolated RECs; however, time-consuming sample preparation made this technique unsuitable for high-throughput studies. Pronase digestion was sufficiently rapid but only yielded 19% (range = 13%) RECs ( n = 6). The nasal brushing method was superior, yielding 92% (range = 15%) RECs ( n = 8) and was equally effective in CF knockout mice (91%, range = 14%, n = 10). Importantly, gene transfer was detectable in brushed RECs from 70% of perfused mice and the number of vector-specific transcripts was comparable to 3.5% of endogenous wild-type Cftr levels. Conclusions Isolation of RECs by brushing allows accurate assessment of GTA transfection efficiency in an experimental system that is relevant for CF gene therapy. Copyright © 2009 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
26. Low-frequency ultrasound increases non-viral gene transfer to the mouse lung.
- Author
-
Xenariou, Stefania, Liang, Hai-Dong, Griesenbach, Uta, Zhu, Jie, Farley, Raymond, Somerton, Lucinda, Singh, Charanjit, Jeffery, Peter K., Scheule, Ronald K., Cheng, Seng H., Geddes, Duncan M., Blomley, Martin, and Alton, Eric W. F. W.
- Published
- 2010
- Full Text
- View/download PDF
27. Surfactant protein-D regulates the postnatal maturation of pulmonary surfactant lipid pool sizes.
- Author
-
Ikegami, Machiko, Grant, Shawn, Korfhagen, Thomas, Scheule, Ronald K., and Whitsett, Jeffrey A.
- Subjects
SURFACE active agents ,PULMONARY surfactant ,HOMEOSTASIS ,LUNGS ,ULTRASTRUCTURE (Biology) ,BILAYER lipid membranes - Abstract
Surfactant protein (SP)-D plays an important role in host defense and pulmonary surfactant homeostasis. In SP-D-deficient (Sftpd
-/- ) mice, the abnormal large surfactant forms seen at the ultrastructural level are taken up inefficiently by type II cells, resulting in an over threefold increase in the surfactant pool size. The mechanisms by which SP-D influences surfactant ultrastructure are unknown. We hypothesized that SP-D binds to surfactant immediately after being secreted and influences surfactant ultrastructure conversion. In newborn and adult sheep lungs, immunogold-labeled SP-D was associated with both lamellated membranous lipid structures of newly secreted surfactant and with small aggregate surfactant but not with tubular myelin. Since SP-D preferentially binds to phosphatidylinositol (PI) in vitro, the postnatal changes in PI were assessed. PI content in the bronchoalveolar lavage fluid increased after birth and peaked at 2-5 days of age, a time of rapid conversion of surfactant forms that is associated with the peak of surfactant lipid pool size. SP-D selectively interacted with PI-rich liposomes in vitro, causing their lysis. Similarly, the abnormal surfactant ultrastructure in Sftpd-/- mice was corrected by the addition of SP-D or melittin, and both peptides caused lysis of lipid vesicles. The normal conversion of surfactant ultrastructure requires SP-D that preferentially interacts with PI-rich, newly secreted surfactant, causing lysis of surfactant lipid membranes, converting the lipid forms into smaller surfactant lamellated structures that are critical for surfactant uptake by type II cells and normal surfactant homeostasis. SP-D regulates the dramatic decreases in the surfactant pool size that occurs in the newborn period. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
28. Role of viral hemagglutinin glycosylation in anti-influenza activities of recombinant surfactant protein D.
- Author
-
Hartshorn, Kevan L., Webby, Richard, White, Mitchell R., Tecle, Tesfaldet, Pan, Clark, Boucher, Susan, Moreland, Rodney J., Crouch, Erika C., and Scheule, Ronald K.
- Subjects
HEMAGGLUTININ ,GLYCOSYLATION ,RECOMBINANT proteins ,INFLUENZA A virus ,INFLUENZA - Abstract
Background: Surfactant protein D (SP-D) plays an important role in innate defense against influenza A viruses (IAVs) and other pathogens. Methods: We tested antiviral activities of recombinant human SP-D against a panel of IAV strains that vary in glycosylation sites on their hemagglutinin (HA). For these experiments a recombinant version of human SP-D of the Met11, Ala160 genotype was used after it was characterized biochemically and structurally. Results: Oligosaccharides at amino acid 165 on the HA in the H3N2 subtype and 104 in the H1N1 subtype are absent in collectin-resistant strains developed in vitro and are important for mediating antiviral activity of SP-D; however, other glycans on the HA of these viral subtypes also are involved in inhibition by SP-D. H3N2 strains obtained shortly after introduction into the human population were largely resistant to SP-D, despite having the glycan at 165. H3N2 strains have become steadily more sensitive to SP-D over time in the human population, in association with addition of other glycans to the head region of the HA. In contrast, H1N1 strains were most sensitive in the 1970s-1980s and more recent strains have become less sensitive, despite retaining the glycan at 104. Two H5N1 strains were also resistant to inhibition by SP-D. By comparing sites of glycan attachment on sensitive vs. resistant strains, specific glycan sites on the head domain of the HA are implicated as important for inhibition by SP-D. Molecular modeling of the glycan attachment sites on HA and the carbohydrate recognition domain of SPD are consistent with these observations. Conclusion: Inhibition by SP-D correlates with presence of several glycan attachment sites on the HA. Pandemic and avian strains appear to lack susceptibility to SP-D and this could be a contributory factor to their virulence. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
29. Surfactant Protein-D and Surfactant Inhibit Endotoxin-Induced Pulmonary lnflammation.
- Author
-
Ikegami, Machiko, Scoville, Elizabeth A., Grant, Shawn, Korfhagen, Thomas, Brondyk, William, Scheule, Ronald K., and Whitsett, Jeffrey A.
- Subjects
ENDOTOXINS ,LUNG diseases ,INFLAMMATION ,RECOMBINANT proteins ,RESPIRATORY diseases - Abstract
The article reports on the results of a study of the effect of exogenous recombinant human surfactant protein-D (rhSP-D) on protection of the adult mouse lung from lipopolysaccharide (LPS)-induced and lipoteichoic acid (LTA)-induced injury. A description of study methods is presented. The study concluded that intratracheal rhSP-D inhibited inflammation induced by intratracheal LPS and LTA instillation in the lung.
- Published
- 2007
- Full Text
- View/download PDF
30. Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo.
- Author
-
Griesenbach, Uta, Kitson, Chris, Garcia, Sara Escudero, Farley, Raymond, Singh, Charanjit, Somerton, Luci, Painter, Hazel, Smith, Rbecca L., Gill, Deborah R., Hyde, Stephen C., Yu-Hua Chow, Hu, Jim, Gray, Mike, Edbrooke, Mark, Ogilvie, Varrie, MacGregor, Gordon, Scheule, Ronald K, Cheng, Seng H., Caplen, Natasha J., and Alton, Eric W. F. W.
- Subjects
SMALL interfering RNA ,OLIGONUCLEOTIDES ,RESPIRATORY organs ,CELLS ,EPITHELIUM ,LABORATORY mice - Abstract
Background: The cationic lipid Genzyme lipid (GL) 67 is the current "gold-standard" for in vivo lung gene transfer. Here, we assessed, if GL67 mediated uptake of siRNAs and asODNs into airway epithelium in vivo. Methods: Anti-lacZ and ENaC (epithelial sodium channel) siRNA and asODN were complexed to GL67 and administered to the mouse airway epithelium in vivo Transfection efficiency and efficacy were assessed using real-time RT-PCR as well as through protein expression and functional studies. In parallel in vitro experiments were carried out to select the most efficient oligonucleotides. Results: In vitro, GL67 efficiently complexed asODNs and siRNAs, and both were stable in exhaled breath condensate. Importantly, during in vitro selection of functional siRNA and asODN we noted that asODNs accumulated rapidly in the nuclei of transfected cells, whereas siRNAs remained in the cytoplasm, a pattern consistent with their presumed site of action. Following in vivo lung transfection siRNAs were only visible in alveolar macrophages, whereas asODN also transfected alveolar epithelial cells, but no significant uptake into conducting airway epithelial cells was seen. SiRNAs and asODNs targeted to β-galactosidase reduced βgal mRNA levels in the airway epithelium of K18-lacZ mice by 30% and 60%, respectively. However, this was insufficient to reduce protein expression. In an attempt to increase transfection efficiency of the airway epithelium, we increased contact time of siRNA and asODN using the in vivo mouse nose model. Although highly variable and inefficient, transfection of airway epithelium with asODN, but not siRNA, was now seen. As asODNs more effectively transfected nasal airway epithelial cells, we assessed the effect of asODN against ENaC, a potential therapeutic target in cystic fibrosis; no decrease in ENaC mRNA levels or function was detected. Conclusion: This study suggests that although siRNAs and asODNs can be developed to inhibit gene expression in culture systems and certain organs in vivo, barriers to nucleic acid transfer in airway epithelial cells seen with large DNA molecules may also affect the efficiency of in vivo uptake of small nucleic acid molecules. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
31. Section 2: CATIONIC LIPOSOMES Chapter 7: Toxicity of Cationic Lipid-DNA Complexes.
- Author
-
Yew, Nelson S., Scheule, Ronald K., Huang, Leaf, Mien-Chie Hung, and Wagner, Ernst
- Abstract
As with any conventional drug, the body's response to cationic lipid-DNA complexes is highly dependent on both the dose administered and the route of delivery. At relatively low doses there is little to no effect on organ function or tissue architecture, but at higher doses, acute inflammation and tissue damage can occur that is sometimes quite profound. Of the two most common routes of delivery, intravenous (IV) or intrapulmonary, IV administration tends to cause more severe adverse effects and can be lethal at higher doses of complex. Both routes activate an innate immune response that includes the induction of proinflammatory cytokines and immune cell activation, a major portion of which has been attributed to the presence of immunostimulatory CpG motifs within the plasmid DNA vector. Removing CpGs from the plasmid vector reduces several, but not all of the acute inflammatory responses to cationic lipid-DNA complexes. Therefore, other strategies are required to improve the therapeutic potential of these vectors, such as transient immune suppression, aerosolization of the complex, and novel formulations that have increased efficiency of transduction and decreased interaction with immune cells. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
32. Partial correction of the α-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
- Author
-
Przybylska, Malgorzata, Wu, I-Huan, Zhao, Hongmei, Ziegler, Robin J., Tousignant, Jennifer D., Desnick, Robert J., Scheule, Ronald K., Cheng, Seng H., and Yew, Nelson S.
- Abstract
Background Fabry disease is a recessive, X-linked disorder caused by a deficiency of the lysosomal enzyme α-galactosidase A, leading to an accumulation of the glycosphingolipid globotriaosylceramide (GL-3) in most tissues of the body. The goal of this study was to determine if systemic delivery of a nonviral vector could correct the enzyme deficiency and reduce the levels of GL-3 in different tissues of a transgenic knockout mouse model of the disease. Methods Cationic lipid was complexed with a CpG-depleted plasmid DNA vector and then injected intravenously into Fabry mice. The levels of α-galactosidase A and GL-3 in different tissues were assayed at various time points after injection. Results Expression of α-galactosidase A was detected in the different tissues of Fabry mice for up to 3 months after complex administration, but resulted in minimal reductions in GL-3 levels. However, the use of the anti-inflammatory drug dexamethasone and multiple dosing increased α-galactosidase A expression and resulted in significant reductions of GL-3 in all the organs with the exception of the kidney. In addition, injecting complex into young Fabry mice partially prevented the normal accumulation of GL-3 in the heart, lung, and liver. Conclusions Systemic delivery of a cationic lipid-pDNA complex partially corrected the enzyme deficiency and reduced glycolipid storage in a mouse model of Fabry disease. The results are one of the few demonstrations of long-term efficacy in a genetic disease model using nonviral vectors. However, substantial improvements in expression, especially in critical organs such as the kidney, are required before these vectors can become a viable approach to treat Fabry disease and other lysosomal storage disorders. Copyright © 2003 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
33. TOXICITY OF CATIONIC LIPOSOME-DNA COMPLEX IN LUNG ISOGRAFTS.
- Author
-
Nagahiro, Itaru, Mora, Bassem N., Boasquevisque, Carlos H. R., Scheule, Ronald K., and Patterson, G. Alexander
- Published
- 2000
- Full Text
- View/download PDF
34. Cationic Lipid Structure and Formulation Considerations for Optimal Gene Transfection of the Lung.
- Author
-
Marshall, John, Nietupski, Jennifer B., Lee, Edward R., Siegel, Craig S., Rafter, Patrick W., Rudginsky, Samantha A., Chang, Chau D., Eastman, Simon J., Harris, David J., Scheule, Ronald K., and Cheng, Seng H.
- Published
- 2000
- Full Text
- View/download PDF
35. Bleomycin stimulation of cytokine secretion by the human alveolar macrophage.
- Author
-
SCHEULE, RONALD K., PERKINS, RAYMOND C., HAMILTON, RAYMOND, and HOLIAN, ANDRIJ
- Published
- 1992
- Full Text
- View/download PDF
36. Effects of continuous high dose rhgm-csf infusion on human monocyte activity.
- Author
-
Perkins, Raymond C., Vadhan-Raj, Saroj, Scheule, Ronald K., Hamilton, Raymond, and Holian, Andrij
- Published
- 1993
- Full Text
- View/download PDF
37. Human Alveolar Macrophage Cytokine Release in Response to in Vitro and in Vivo Asbestos Exposure.
- Author
-
Perkins, Raymond C., Scheule, Ronald K., Hamilton, Raymond, Gomes, Glen, Freidman, Gary, and Holian, Andrij
- Published
- 1993
- Full Text
- View/download PDF
38. Immunologic Aspects of Pneumoconiosis.
- Author
-
Scheule, Ronald K. and Holian, Andrij
- Published
- 1991
- Full Text
- View/download PDF
39. Reconstitution of membranes with fractions of triton X-100 which are easily removed
- Author
-
Scheule, Ronald K. and Gaffney, Betty Jean
- Published
- 1981
- Full Text
- View/download PDF
40. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann–Pick C mice
- Author
-
Nietupski, Jennifer B., Pacheco, Joshua J., Chuang, Wei-Lien, Maratea, Kimberly, Li, Lingyun, Foley, Joseph, Ashe, Karen M., Cooper, Christopher G.F., Aerts, Johannes M.F.G., Copeland, Diane P., Scheule, Ronald K., Cheng, Seng H., and Marshall, John
- Subjects
- *
NEURODEGENERATION , *NIEMANN-Pick diseases , *IMINOSUGARS , *GLUCOSYLCERAMIDES , *ENZYME inhibitors , *LABORATORY mice , *GLYCOSPHINGOLIPIDS , *GENETIC mutation - Abstract
Abstract: Niemann Pick type C (NPC) disease is a progressive neurodegenerative disease caused by mutations in NPC1 or NPC2, the gene products of which are involved in cholesterol transport in late endosomes. NPC is characterized by an accumulation of cholesterol, sphingomyelin and glycosphingolipids in the visceral organs, primarily the liver and spleen. In the brain, there is a redistribution of unesterified cholesterol and a concomitant accumulation of glycosphingolipids. It has been suggested that reducing the aberrant lysosomal storage of glycosphingolipids in the brain by a substrate reduction therapy (SRT) approach may prove beneficial. Inhibiting glucosylceramide synthase (GCS) using the iminosugar-based inhibitor miglustat (NB-DNJ) has been reported to increase the survival of NPC mice. Here, we tested the effects of Genz-529468, a more potent iminosugar-based inhibitor of GCS, in the NPC mouse. Oral administration of Genz-529468 or NB-DNJ to NPC mice improved their motor function, reduced CNS inflammation, and increased their longevity. However, Genz-529468 offered a wider therapeutic window and better therapeutic index than NB-DNJ. Analysis of the glycolipids in the CNS of the iminosugar-treated NPC mouse revealed that the glucosylceramide (GL1) but not the ganglioside levels were highly elevated. This increase in GL1 was likely caused by the off-target inhibition of the murine non-lysosomal glucosylceramidase, Gba2. Hence, the basis for the observed effects of these inhibitors in NPC mice might be related to their inhibition of Gba2 or another unintended target rather than a result of substrate reduction. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
41. Systemic Administration of AAV8-α-galactosidase A Induces Humoral Tolerance in Nonhuman Primates Despite Low Hepatic Expression.
- Author
-
Nietupski, Jennifer B, Hurlbut, Gregory D, Ziegler, Robin J, Chu, Qiuming, Hodges, Bradley L, Ashe, Karen M, Bree, Mark, Cheng, Seng H, Gregory, Richard J, Marshall, John, and Scheule, Ronald K
- Subjects
- *
GALACTOSE , *SEROTYPES , *PROTEINS , *BILIARY tract , *MESSENGER RNA - Abstract
In mice, liver-restricted expression of lysosomal enzymes from adeno-associated viral serotype 8 (AAV8) vectors results in reduced antibodies to the expressed proteins. To ask whether this result might translate to patients, nonhuman primates (NHPs) were injected systemically with AAV8 encoding α-galactosidase A (α-gal). As in mice, sustained expression in monkeys attenuated antibody responses to α-gal. However, this effect was not robust, and sustained α-gal levels were 1-2 logs lower than those achieved in male mice at the same vector dose. Because our mouse studies had shown that antibody levels were directly related to expression levels, several strategies were evaluated to increase expression in monkeys. Unlike mice, expression in monkeys did not respond to androgens. Local delivery to the liver, immune suppression, a self-complementary vector and pharmacologic approaches similarly failed to increase expression. While equivalent vector copies reached mouse and primate liver and there were no apparent differences in vector form, methylation or deamination, transgene expression was limited at the mRNA level in monkeys. These results suggest that compared to mice, transcription from an AAV8 vector in monkeys can be significantly reduced. They also suggest some current limits on achieving clinically useful antibody reduction and therapeutic benefit for lysosomal storage diseases using a systemic AAV8-based approach. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
42. Induction of Immune Tolerance to a Therapeutic Protein by Intrathymic Gene Delivery.
- Author
-
Qiuming Chu, Moreland, Rodney J., Lan Gao, Taylor, Kristin M., Meyers, Elizabeth, Cheng, Seng H., and Scheule, Ronald K.
- Subjects
- *
IMMUNOLOGICAL tolerance , *IMMUNE response , *PROTEINS , *GENETIC disorders , *T cells , *MESSENGER RNA - Abstract
The efficacy of recombinant enzyme therapy for genetic diseases is limited in some patients by the generation of a humoral immune response to the therapeutic protein. Inducing immune tolerance to the protein prior to treatment has the potential to increase therapeutic efficacy. Using an AAV8 vector encoding human acid α-glucosidase (hGAA), we have evaluated direct intrathymic injection for inducing tolerance. We have also compared the final tolerogenic states achieved by intrathymic and intravenous injection. Intrathymic vector delivery induced tolerance equivalent to that generated by intravenous delivery, but at a 25-fold lower dose, the thymic hGAA expression level was 10,000-fold lower than the liver expression necessary for systemic tolerance induction. Splenic regulatory T cells (Tregs) were apparent after delivery by both routes, but with different phenotypes. Intrathymic delivery resulted in Tregs with higher FoxP3, TGFβ, and IL-10 mRNA levels. These differences may account for the differences noted in splenic T cells, where only intravenous delivery appeared to inhibit their activation. Our results imply that different mechanisms may be operating to generate immune tolerance by intrathymic and intravenous delivery of an AAV vector, and suggest that the intrathymic route may hold promise for decreasing the humoral immune response to therapeutic proteins in genetic disease indications. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
43. Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy.
- Author
-
Hurlbut, Gregory D., Ziegler, Robin J., Nietupski, Jennifer B., Foley, Joseph W., Woodworth, Lisa A., Meyers, Elizabeth, Bercury, Scott D., Pande, Nilesh N., Souza, David W., Bree, Mark P., Lukason, Michael J., Marshall, John, Cheng, Seng H., and Scheule, Ronald K.
- Subjects
- *
LIVER diseases , *GENE expression , *PRIMATE physiology , *ADENOVIRUS diseases , *IMMUNOGENETICS , *LABORATORY mice , *IMMUNOGLOBULINS , *GENE therapy , *THERAPEUTICS - Abstract
Liver-directed gene therapy with adeno-associated virus (AAV) vectors effectively treats mouse models of lysosomal storage diseases (LSDs). We asked whether these results were likely to translate to patients. To understand to what extent preexisting anti-AAV8 antibodies could impede AAV8-mediated liver transduction in primates, commonly preexposed to AAV, we quantified the effects of preexisting antibodies on liver transduction and subsequent transgene expression in mouse and nonhuman primate (NHP) models. Using the highest viral dose previously reported in a clinical trial, passive transfer of NHP sera containing relatively low anti-AAV8 titers into mice blocked liver transduction, which could be partially overcome by increasing vector dose tenfold. Based on this and a survey of anti-AAV8 titers in 112 humans, we predict that high-dose systemic gene therapy would successfully transduce liver in >50% of human patients. However, although high-dose AAV8 administration to mice and monkeys with equivalent anti-AAV8 titers led to comparable liver vector copy numbers, the resulting transgene expression in primates was ~1.5-logs lower than mice. This suggests vector fate differs in these species and that strategies focused solely on overcoming preexisting vector-specific antibodies may be insufficient to achieve clinically meaningful expression levels of LSD genes using a liver-directed gene therapy approach in patients. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
44. Evaluation of Systemic Follistatin as an Adjuvant to Stimulate Muscle Repair and Improve Motor Function in Pompe Mice.
- Author
-
Foley, Joseph W., Bercury, Scott D., Finn, Patrick, Cheng, Seng H., Scheule, Ronald K., and Ziegler, Robin J.
- Subjects
- *
HYPERTROPHY , *GLYCOGEN storage disease , *GLUCOSIDASES , *MOLECULAR genetics , *MOTOR ability , *FOLLISTATIN , *LABORATORY mice , *GENE therapy - Abstract
Due to the lack of acid α-glucosidase (GAA) activity, Pompe mice develop glycogen storage pathology and progressive skeletal muscle dysfunction with age. Applying either gene or enzyme therapy to reconstitute GAA levels in older, symptomatic Pompe mice effectively reduces glycogen storage in skeletal muscle but provides only modest improvements in motor function. As strategies to stimulate muscle hypertrophy, such as by myostatin inhibition, have been shown to improve muscle pathology and strength in mouse models of muscular dystrophy, we sought to determine whether these benefits might be similarly realized in Pompe mice. Administration of a recombinant adeno-associated virus serotype 8 vector encoding follistatin, an inhibitor of myostatin, increased muscle mass and strength but only in Pompe mice that were treated before 10 months of age. Younger Pompe mice showed significant muscle fiber hypertrophy in response to treatment with follistatin, but maximal gains in muscle strength were achieved only when concomitant GAA administration reduced glycogen storage in the affected muscles. Despite increased grip strength, follistatin treatment failed to improve rotarod performance. These findings highlight the importance of treating Pompe skeletal muscle before pathology becomes irreversible, and suggest that adjunctive therapies may not be effective without first clearing skeletal muscle glycogen storage with GAA. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
45. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease
- Author
-
Ashe, Karen M., Taylor, Kristin M., Chu, Qiuming, Meyers, Elizabeth, Ellis, Allen, Jingozyan, Varvara, Klinger, Katherine, Finn, Patrick F., Cooper, Christopher G.F., Chuang, Wei-Lien, Marshall, John, McPherson, John M., Mattaliano, Robert J., Cheng, Seng H., Scheule, Ronald K., and Moreland, Rodney J.
- Subjects
- *
GLYCOGEN storage disease type II , *ETIOLOGY of diseases , *GLUCOSIDASES , *GLYCOGEN , *BIOSYNTHESIS , *RAPAMYCIN , *IMMUNOSUPPRESSIVE agents , *THERAPEUTICS - Abstract
Abstract: Pompe disease, also known as glycogen storage disease (GSD) type II, is caused by deficiency of lysosomal acid α-glucosidase (GAA). The resulting glycogen accumulation causes a spectrum of disease severity ranging from a rapidly progressive course that is typically fatal by 1–2years of age to a more slowly progressive course that causes significant morbidity and early mortality in children and adults. Recombinant human GAA (rhGAA) improves clinical outcomes with variable results. Adjunct therapy that increases the effectiveness of rhGAA may benefit some Pompe patients. Co-administration of the mTORC1 inhibitor rapamycin with rhGAA in a GAA knockout mouse reduced muscle glycogen content more than rhGAA or rapamycin alone. These results suggest mTORC1 inhibition may benefit GSDs that involve glycogen accumulation in muscle. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
46. Systemic Insulin-like Growth Factor-1 Reverses Hypoalgesia and Improves Mobility in a Mouse Model of Diabetic Peripheral Neuropathy.
- Author
-
Chu, Qiuming, Moreland, Rod, Yew, Nelson S, Foley, Joseph, Ziegler, Robin, and Scheule, Ronald K
- Subjects
- *
GENE therapy , *DEMYELINATION , *MICE , *NEUROPATHY , *LABORATORY animals , *PREVENTIVE medicine , *PAIN , *HYPERALGESIA , *THERAPEUTICS - Abstract
Peripheral neuropathy is a particularly debilitating complication of both type 1 and type 2 diabetes characterized by sensory and motor neuron damage and decreased circulating levels of insulin-like growth factor 1 (IGF-1). Quite often, an early hyperalgesia is followed by hypoalgesia and muscle weakness. Hypoalgesia can lead to significant morbidity for which there is no current treatment. Hyperglycemic, streptozotocin (STZ)-induced rodent models reproduce these symptoms. We investigated whether increasing systemic IGF-1 could improve neuronal function in hyper- and hypoalgesic STZ-treated mice. Increased circulating levels of IGF-1 were achieved by delivering a plasmid or adeno-associated viral (AAV) vector bearing mouse IGF-1 to the liver. Treating mice in the hyperalgesia stage prevented later hypoalgesia. Treating mice in the hypoalgesia stage reversed existing hypoalgesia. This latter effect could be seen by merely restoring IGF-1 serum levels to normalcy, which was possible to achieve by IGF-1 gene therapy or insulin treatment. Sensory nerve functional correction was seen to be correlated with attenuated Schwann cell vacuolization and demyelination in peripheral sensory nerve fibers. A further increase in serum IGF-1 levels with gene therapy also improved motor function, consistent with the observed prevention of both muscle atrophy and peripheral motor nerve fiber demyelination. These results suggest that the restoration of systemic levels of IGF-1 may prove to be a highly effective therapeutic modality for treating diabetic peripheral neuropathy.Molecular Therapy (2008) 16 8, 1400–1408 doi:10.1038/mt.2008.115 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
47. Timing of Therapeutic Intervention Determines Functional and Survival Outcomes in a Mouse Model of Late Infantile Batten Disease.
- Author
-
Cabrera-Salazar, Mario A., Roskelley, Eric M., Jie Bu, Hodges, Bradley L., Yew, Nelson, Dodge, James C., Shihabuddin, Lamya S., Sohar, Istvan, Sleat, David E., Scheule, Ronald K., Davidson, Beverly L., Cheng, Seng H., Lobel, Peter, and Passini, Marco A.
- Subjects
- *
NEURONAL ceroid-lipofuscinosis , *PEPTIDASE , *ADENOVIRUSES , *NEURONS , *GENETIC mutation - Abstract
Classical late infantile neuronal ceroid lipofuscinosis (cLINCL) is a monogenic disorder caused by the loss of tripeptidyl peptidase 1 (TPP1) activity as a result of mutations in CLN2. Absence of TPP1 results in lysosomal storage with an accompanying axonal degeneration throughout the central nervous system (CNS), which leads to progressive neurodegeneration and early death. In this study, we compared the efficacies of pre- and post-symptomatic injections of recombinant adeno-associated virus (AAV) for treating the cellular and functional abnormalities of CLN2 mutant mice. Intracranial injection of AAV1-hCLN2 resulted in widespread human TPP1 (hTPP1) activity in the brain that was 10–100-fold above wild-type levels. Injections before disease onset prevented storage and spared neurons from axonal degeneration, reflected by the preservation of motor function. Furthermore, the majority of CLN2 mutant mice treated pre-symptomatically lived for at least 330 days, compared with a median survival of 151 days in untreated CLN2 mutant controls. In contrast, although injection after disease onset ameliorated lysosomal storage, there was evidence of axonal degeneration, motor function showed limited recovery, and the animals had a median lifespan of 216 days. These data illustrate the importance of early intervention for enhanced therapeutic benefit, which may provide guidance in designing novel treatment strategies for cLINCL patients.Molecular Therapy (2007) 15 10, 1782–1788. doi:10.1038/sj.mt.6300249 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
48. Local Delivery of a Viral Vector Mitigates Neutralization by Antiviral Antibodies and Results in Efficient Transduction of Rabbit Liver
- Author
-
Hodges, Bradley L., Taylor, Kristin M., Chu, Qiuming, Scull, Samantha E., Serriello, Rebecca G., Anderson, Scott C., Wang, Fei, and Scheule, Ronald K.
- Subjects
- *
BILIARY tract , *IMMUNOGLOBULINS , *MICROBIAL genetics , *GENETIC transformation - Abstract
Abstract: Antiviral antibodies within the human population remain a barrier to the effective clinical use of viral gene transfer vectors. We have asked whether local, balloon catheter-mediated delivery of a viral vector to the rabbit liver using a hepatic vein might mitigate the neutralizing effects of antiviral antibodies. We have compared directly the ability of adenovirus (Ad2) encoding nuclear-localized β-galactosidase to infect the rabbit liver after local and systemic delivery in both the presence and the absence of defined anti-Ad2 antibody titers. In naive rabbits, local delivery resulted in higher β-galactosidase expression compared to systemic delivery. In the presence of passively administered anti-Ad2 antibodies, local delivery resulted in expression levels that were comparable to those obtained in naive rabbits by systemic delivery. Local delivery also resulted in the majority of expression originating from hepatocytes, even in passively immunized animals, a result that could not be duplicated using the systemic approach. Since systemic delivery of adenovirus in naive animal models results in transgene expression levels often regarded as therapeutic, these results predict that local hepatic vein delivery of a viral vector is a clinically practical approach to mitigate neutralizing antiviral antibodies and generate therapeutic levels of transgene expression. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
49. Transient siRNA-Mediated Attenuation of Liver Expression from an α-Galactosidase a Plasmid Reduces Subsequent Humoral Immune Responses to the Transgene Product in Mice
- Author
-
Chu, Qiuming, Joseph, Macy, Przybylska, Malgorzata, Yew, Nelson S., and Scheule, Ronald K.
- Subjects
- *
BILIARY tract , *MOBILE genetic elements , *GENETIC engineering , *IMMUNOGLOBULINS - Abstract
Abstract: Hepatocytes are an effective depot for protein production from gene therapy vectors. However, when gene transfer vectors or their delivery induces hepatic inflammation, adaptive immune responses against the transgene product can ensue. In BALB/c mice, hydrodynamic delivery of a CMV-driven plasmid DNA (pDNA) bearing human α-galactosidase A (αgal) to the liver generated antibodies against αgal. This humoral immune response was more robust in a transgenic knockout for αgal, the Fabry mouse. The antibody response could be attenuated in both mouse strains by using a promoter more restricted to hepatocytes. In an attempt to reduce further the humoral responses to αgal, expression from the transgene was attenuated by using siRNA during the period of initial delivery-associated liver inflammation. In both mouse models and with both promoters, codelivering an αgal siRNA resulted in a 2 log decrease in initial expression that then increased over the next few weeks to levels generated by the pDNA alone. This strategy led to both attenuated antibodies and an immune status approximating “tolerance” to αgal. Importantly, in the Fabry mouse, an αgal siRNA together with a hepatocyte-restricted promoter gave minimal anti-αgal antibodies and profound tolerance, suggesting that such an approach might have clinical utility for genetic diseases. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
50. Long-term Transgene Expression from Plasmid DNA Gene Therapy Vectors Is Negatively Affected by CpG Dinucleotides
- Author
-
Hodges, Bradley L., Taylor, Kristin M., Joseph, Macy F., Bourgeois, Sarah A., and Scheule, Ronald K.
- Subjects
- *
GENE therapy , *GENETIC engineering , *HEMOPHILIA , *BLOOD diseases - Abstract
CpG-reduced, CMV-based plasmid DNA constructs encoding human α-galactosidase A and factor IX were injected into C57Bl/6, BALB/c, and CD1 mice using hydrodynamics-based delivery of plasmid DNA (pDNA), and gene expression was monitored for 6 months. Linearized and supercoiled pDNAs were compared for their abilities to support long-term expression and to generate immune responses to the transgene product. In all mouse strains supercoiled CpG-reduced pDNA encoding α-galactosidase A and factor IX generated higher and more sustained levels of circulating gene product than their supercoiled CpG-replete analogs. Linearizing supercoiled CpG-reduced pDNA did not significantly increase levels of circulating gene product beyond levels supercoiled CpG-reduced pDNA could achieve. Linearizing supercoiled CpG-replete pDNA vectors significantly increased expression compared to their supercoiled CpG-replete analogs, but the increase was short-lived or subtherapeutic. Regardless of vector, liver depot expression did not elicit significant antibody responses to human α-galactosidase A or factor IX. Taken together, these data suggest that a clinically acceptable hydrodynamics-based approach targeting the liver combined with CpG-reduced pDNA vectors may represent a viable option for individuals with hemophilia, a lysosomal storage disease, or other disease in which prolonged depot expression of a therapeutic protein from the liver is desirable. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.